Ad is loading...
MENU

PDSB Stock Tickeron detected bearish Stock Pattern: Triangle Symmetrical Bottom PDSB on November 11, 2024, netting in a 15.23% gain over 2 days

A.I.dvisor
at Tickeron.com
Loading...
+15.23% Gain from a Successful pattern Triangle Symmetrical Bottom
PDSB - PDS Biotechnology Corp
Tickeron
Ticker: PDSB
Company: PDS Biotechnology
Gain from shortening: +15.23%
Confirmed: 11/11/24
Succeeded: 11/13/24
Total length: 2 days
On November 11, 2024, A.I.dvisor detected a Triangle Symmetrical Bottom Pattern (Bearish) for PDS Biotechnology Corp (PDSB, $3.25). On November 11, 2024, A.I.dvisor confirmed the Bearish pattern, setting a target price of the stock. On November 13, 2024, the stock hit the target price of $1.95 – resulting in a +1 gain for traders who shorted the stock on the pattern detection date.

Momentum Indicator for PDSB turns negative, indicating new downward trend

PDSB saw its Momentum Indicator move below the 0 level on November 11, 2024. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 76 similar instances where the indicator turned negative. In of the 76 cases, the stock moved further down in the following days. The odds of a decline are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for PDSB turned negative on November 12, 2024. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at .

PDSB moved below its 50-day moving average on November 11, 2024 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for PDSB crossed bearishly below the 50-day moving average on October 22, 2024. This indicates that the trend has shifted lower and could be considered a sell signal. In of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PDSB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where PDSB advanced for three days, in of 259 cases, the price rose further within the following month. The odds of a continued upward trend are .

PDSB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.444) is normal, around the industry mean (13.752). P/E Ratio (0.000) is within average values for comparable stocks, (88.017). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.790). PDSB has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (0.000) is also within normal values, averaging (224.437).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. PDSB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PDSB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
PDSB
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of clinical-stage immunotherapies to treat various early-stage and late-stage cancers which includes head & neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer and related cancers

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
303A College Road
Phone
+1 800 208-3343
Employees
25
Web
https://www.pdsbiotech.com